DDInter1592 DDInter32
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim .
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is regulated by {v} (Gene) ERBB4
ERBB4 {u} (Gene) is bound by {v} (Compound) Afatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) regulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Afatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Rifapentine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) regulates {v} (Gene) KEAP1
KEAP1 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Afatinib
Rifapentine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Afatinib
Rifapentine {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Afatinib
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Afatinib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Rifapentine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is regulated by ERBB4 (Gene) and ERBB4 (Gene) is bound by Afatinib (Compound)
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) regulates ABL1 (Gene) and ABL1 (Gene) is bound by Afatinib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Rifapentine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) regulates KEAP1 (Gene) and KEAP1 (Gene) is upregulated by Afatinib (Compound)
Rifapentine (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Afatinib (Compound)
Rifapentine (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)